

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

CanSino Biologics Inc.
康希諾生物股份公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock code: 6185)

VOLUNTARY ANNOUNCEMENT

**NATIONAL MEDICAL PRODUCTS ADMINISTRATION'S APPROVAL OF
CLINICAL TRIAL APPLICATION FOR COVID-19 MRNA VACCINE**

This announcement is made by CanSino Biologics Inc. (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis.

The Company is pleased to announce that, the clinical trial application for the COVID-19 mRNA vaccine developed by the Group was approved by the National Medical Products Administration of China. Results of pre-clinical studies showed that, such vaccine can induce high-titer neutralizing antibodies against multiple SARS-CoV-2 variants of concern identified by World Health Organization, including the current dominant strain. Compared with the current original strain-based COVID-19 vaccines, our COVID-19 mRNA vaccine can elicit neutralizing antibodies with better cross-variant reactivity, and is expected to provide more effective protection against infections caused by circulating variants.

The Group is planning a layout of a variety of innovative preventive vaccine products pipeline with proprietary intellectual property rights and is focusing on the development of preventive and therapeutic biological products through its mRNA platform. Compared with traditional vaccine technology platforms, the mRNA technology industrialized platform has significant advantages in research and development process and production cycles. Upon completion of the mRNA technology platform, such platform is expected to be of great value as a domestic substitute for those provided by leading international biopharmaceutical companies in this field.

Cautionary Statement required by Rule 18A.05 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited: The safety and efficacy of the COVID-19 mRNA vaccine is subject to confirmation by clinical trials and we cannot guarantee that we will ultimately develop or commercialize the COVID-19 mRNA vaccine successfully. Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

By order of the Board
CanSino Biologics Inc.
Xuefeng YU
Chairman

Hong Kong, April 4, 2022

As of the date of this announcement, the board of directors comprises Dr. Xuefeng YU, Dr. Shou Bai CHAO, Dr. Tao ZHU, Dr. Dongxu QIU and Ms. Jing WANG as executive directors, Mr. Liang LIN, Ms. Nisa Bernice Wing-Yu LEUNG and Mr. Zhi XIAO as non-executive directors, and Mr. Shiu Kwan Danny WAI, Ms. Zhu XIN, Mr. Shuifa GUI and Mr. Jianzhong LIU as independent non-executive directors.